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A Proteomic Approach to Analyze the
Aspirin-mediated Lysine Acetylome*□S
Michael H. Tatham‡, Christian Cole§, Paul Scullion¶, Ross Wilkie‡‡,
Nicholas J. Westwood, Lesley A. Stark**, and Ronald T. Hay‡§§
Aspirin, or acetylsalicylic acid is widely used to control
pain, inflammation and fever. Important to this function is
its ability to irreversibly acetylate cyclooxygenases at ac-
tive site serines. Aspirin has the potential to acetylate
other amino acid side-chains, leading to the possibility
that aspirin-mediated lysine acetylation could explain
some of its as-yet unexplained drug actions or side-ef-
fects. Using isotopically labeled aspirin-d3, in combination
with acetylated lysine purification and LC-MS/MS, we
identified over 12000 sites of lysine acetylation from cul-
tured human cells. Although aspirin amplifies endogenous
acetylation signals at the majority of detectable endoge-
nous sites, cells tolerate aspirin mediated acetylation very
well unless cellular deacetylases are inhibited. Although
most endogenous acetylations are amplified by orders of
magnitude, lysine acetylation site occupancies remain
very low even after high doses of aspirin. This work shows
that while aspirin has enormous potential to alter protein
function, in the majority of cases aspirin-mediated acety-
lations do not accumulate to levels likely to elicit biolog-
ical effects. These findings are consistent with an emerg-
ing model for cellular acetylation whereby stoichiometry
correlates with biological relevance, and deacetylases act
to minimize the biological consequences of nonspecific
chemical acetylations. Molecular & Cellular Proteomics
16: 10.1074/mcp.O116.065219, 310–326, 2017.
Aspirin, also known as acetylsalicylic acid (ASA)1 is the
most widely used drug in the world (1) and is taken to treat
acute pain, fever and inflammation. It also has long term
applications in the prophylactic treatment of heart attacks,
strokes, and pathological blood clot formation (2). An emerg-
ing role for aspirin is in the prevention of some malignant
transformations, such as colorectal cancer (3–6). Aspirin ad-
ministration can be associated with various undesirable side-
effects including gastrointestinal bleeding, ulcerations, neph-
rotoxicity and tinnitus.
Aspirin is a non-steroidal anti-inflammatory drug (NSAID),
and is the only NSAID known to function by irreversible mod-
ification of the cyclooxygenases COX-1 and COX-2. Acetyla-
tion at active site serines 530 and 516 respectively, inhibits
prostaglandin and thromboxane synthesis (7, 8). Aspirin has
also been shown to acetylate the -amino-group of lysine
side-chains in cellular and extracellular proteins including se-
rum albumin (9), fibrinogen (10), hemoglobin (11), p53 (12) and
glucose-6-phosphate dehydrogenase (13, 14). Work using
radiolabeled aspirin (15), and acetylated lysine (AcK)-specific
antibodies (16) has shown that aspirin can acetylate cellular
and extracellular proteins. Considering the salience of revers-
ible enzymatic protein acetylation (17), these observations
lend weight to the hypothesis that aspirin-mediated lysine
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acetylation may explain some of the currently unexplained
functions of the drug (16).
To date, proteomic approaches to identify sites of protein
acetylation by aspirin have either lacked site-level data (14,
18), or used chemically modified forms of aspirin with un-
known consequences on drug action (19). Critically, the ex-
tent of acetylation has not been investigated even at the single
protein level, and so aspirin’s true potential to interfere with
cellular systems via acetylation is still unclear.
We have developed a method that employs a highly specific
peptide enrichment strategy in combination with isotopically
labeled aspirin-d3 that does not alter its chemical reactivity.
This allows unambiguous, proteome-wide analysis of aspirin-
mediated lysine acetylation in any biological context. We
identified over 12,000 AcK-d3 sites in 3763 proteins from
HeLa cells, and show that most detectable endogenous
acetylations, with exception of histone N-terminal tails, are
greatly enhanced by aspirin. However, this huge up-regulation
of cellular acetylation still only influences a very small propor-
tion of any particular protein, as site occupancies are below
1% for the vast majority of acetylations. We found that aspi-
rin-mediated acetylations are mainly opposed by the action of
endogenous deacetylases, and inhibition of HDAC6 enhances
aspirin acetylations and increases aspirin-mediated cytotox-
icity. These findings show that the endogenous deacetylase
system is capable of blunting aspirin’s acetylation potential
and highlight the considerable task involved in pinpointing
acetylations that may explain currently obscure modes of
aspirin action.
EXPERIMENTAL PROCEDURES
Cell Survival Assays—Approximately 20,000 HeLa cells per well
were seeded in a 96-well, white, flat-bottomed tissue-culture plate
(Sigma, UK) in a volume of 100 l culture medium (DMEM lacking
phenol red, (Thermo Fisher Scientific, UK) supplemented with 2 mM
glutamine and 10% fetal calf serum, plus penicillin/streptomycin).
Cells were incubated for 18 h at 37 °C at 5% CO2. Dilutions of either
aspirin or salicylic acid were made in culture medium to final concen-
trations of 20 mM, 10 mM, 5 mM, 2 mM, 1 mM, and 0.5 mM. A zero drug
dilution was made containing only DMSO at the same concentration
as in the dilutions (aspirin and SA were dissolved and stored in
DMSO). To begin exposure to salicylate cell culture medium was
replaced with the salicylate dilutions in quadruplicate. Cells were
cultured at 37 °C and 5% CO2 for 6, 24, or 48 h. To assess cell
viability 100 l ATP assay buffer (50 mM Tris/phosphate pH 7.8, 16
mM MgCl2, 2 mM DTT, 2% v/v Triton-X-100, 30% v/v (37.8% w/v)
glycerol, 1% w/v BSA, 0.25 mM D-luciferin, 8 M sodium pyrophos-
phate tetra-basic decahydrate, 500 ng/ml Luciferase) was added to
each well, before sealing with clear film and agitating at 900 rpm and
20 °C for 10 min. Luminescence was measured using an EnVision
Multilabel plate reader (Perkin Elmer, UK). Readings were normalized
to the zero-drug control for each set of replicates. In experiments
using co-treatment with KDAC inhibitors, bufexamac was used at
0.25 mM or nicotinamide at 20 mM, cells were exposed for 24 h, and
salicylate dilutions of 20 mM, 10 mM, 5 mM, 2.5 mM, 1.25 mM, and
0.625 mM were used.
Synthesis of Aspirin-d3—2.18 g salicylic acid (Sigma Aldrich) was
mixed with 5g acetic anhydride-d6 (Sigma Aldrich) in an Erlenmeyer
flask before addition of 8 drops (400 l) of 85% orthophosphoric
acid. The solution was mixed by agitation and warmed to 70 °C in a
water bath for 15 min. Unreacted acetic anhydride-d6 was destroyed
by addition of 14 drops (700 l) cold ultra-pure water. Crystallization
was initiated by addition of 14.5 ml ultra-pure water and transfer of
the solution to an ice-bath for 30 min. Crystals of aspirin-d3 were
removed from solution by filtration onto filter paper under suction on
a Buckner funnel. Crystals were washed with 20 ml ice-cold ultra-
pure water, then dried by 15 min suction. Recrystallization of Aspi-
rin-d3 was then performed: The crystals were dissolved in 10 ml
ethanol while gently warming. Recrystallization was triggered by ad-
dition of 27 ml warm ultra-pure water, followed by slow cooling at
ambient temperature, then rapid cooling on ice. Crystals were filtered
out of solution onto filter paper using a Buchner funnel and suction for
15 min, then dried on a fresh sheet of filter paper in a glass beaker
loosely covered with tissue-paper for 2 days. Unlabeled Aspirin was
synthesized by an identical method.
NMR Analysis of Aspirin—1H and 13C spectra were obtained with a
Bruker Avance II 400 MHz, Bruker Avance 500 MHz or a Bruker
Avance III 500 MHz spectrometer with the solvent peak used as the
internal standard. NMR spectra were processed using TopSpin 3.1
(PC version) or MestReNova.
MS Analysis of Aspirin—Saturated solutions of commercially
sourced aspirin, in house synthesized aspirin, and in house synthe-
sized aspirin-d3 were made in acetonitrile. 1:1000 dilutions in aceto-
nitrile of each was analyzed on a QExactive mass spectrometer in
negative mode using a direct infusion flow rate of 20 lmin1, linked
to a HESI-II probe in Ion Max API source (Thermo Scientific) running
at 4 kV, 300 °C and S-lens RF level of 50. Settings for full MS scans
were; scan range  172–185 m/z, resolution  70000, AGC target 
1e6, maximum injection time  20ms. Spectra were acquired over 25
scans and viewed in Xcalibur Qual Browser.
Kinetic Analysis of Aspirin and Salicylic Acid in Cultured Cells and
Cell Medium—HeLa cells were cultured in six well plates (9.5 cm2
area per well) in DMEM supplemented with FCS to 10% such that
final cell counts at the end of the time-course were 1 to 1.5 million.
Cells were exposed to 5 mM aspirin (unlabeled) for 0.25, 0.5, 1, 2, 6,
16, or 24 h by replacement of 2 ml medium. To assess concentrations
of aspirin (ASA) and salicylic acid (SA) in both culture medium and
cells the following method was used for each well of cultured cells: 1
ml culture medium was removed and snap-frozen before storage at
80 °C. The remaining medium was removed and the cells washed
three times with 1 ml ice-cold PBS. Cells were lysed by addition of
100 l lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% triton-X100,
plus Roche protease inhibitor mixture), and incubated on ice with
orbital shaking for 10 min. Lysates were removed from wells and
snap frozen before storage at 80 °C. This process was repeated in
triplicate (n  3) for each time point. For each time point a fourth well
of cells was grown in parallel to allow estimation of cell numbers and
cell volume using an automated cell counter (Countess, Invitrogen,
UK). These values were used to calculate total cell volume, which was
between 2 and 3 l depending on the time point.
ASA and SA were measured in medium and lysate samples using
UV absorption with in-line UPLC (Acquity) running a BEH-C18 50 
2.1 mm 1.7 m particle column. A 3 min gradient protocol was used
running from 2 to 95% acetonitrile (in 0.1% formic acid) then back to
2%. For our system SA presented a max 304 nm and retention time
(RT) 1.49 min and ASA a max  276 nm at RT 1.42 min. Calibration
curves were defined over a range of ASA and SA concentrations from
0.1 to 1000 g/ml. Sample concentrations of ASA and SA were
calculated by reference to these calibration curves.
Measured data were modeled using Copasi (v4.16 - build 104) (20).
Data were fit to a simple model for the diffusion of aspirin and salicylic
acid between medium and cells and for the hydrolysis of aspirin in
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both compartments as shown in supplemental Fig. S1A. The five
species shown in supplemental Fig. S1A, and two compartments
were defined; Medium (2 ml) and cells (2 l). Experimental data were
weighted manually toward the more confident measurements from
the culture medium (weight 1.0), and away from the cellular measure-
ments (weight 0.2) due to both the inherent errors of the lower
concentration measurements (actual concentration measurements in
the cell extracts were in the order of 10 times lower than for the
medium measurements) and the fact that these values included the
extra variable of cell counting and size measurements. The seven rate
constants shown in supplemental Fig. S1A were modeled along with
the starting concentrations of SA and ASA in the medium. All other
starting concentrations were fixed at zero. The in and out rate con-
stants for ASA were constrained to be equal, as were those for SA.
Repeated iterations of parameter estimation resulted in the fits shown
in supplemental Fig. S1B, and the final rate constant values shown in
supplemental Fig. S1C. Parameter scanning was used to predict the
effect of the starting concentration of aspirin in the medium on the
maximum cellular concentration of aspirin (supplemental Fig. S1E).
Antibodies—Anti-acetylated lysine antibody (250 g.ml1) (Immune-
Chem, Burnaby, Canada) was used at 1:2000 dilutions 16 h 4 °C in
immunoblotting experiments. Anti-Rabbit HRP (Sigma) was used as
secondary antibody at 1:2000 dilutions for 1 h at room temperature.
Purification of Acetylated Peptides from Cultured Human Cells—
Twenty-one 150 mm diameter plates were used to culture HeLa cells
to 70% confluency in 20 ml DMEM, 10% FCS. In batches of seven
plates, the cells were exposed for 6 h with DMSO only, aspirin in
DMSO or aspirin-d3 in DMSO, to a final DMSO concentration of
0.13% and aspirin concentration of 5 mM. Cells were washed three
times with PBS and for each set of seven plates, the resultant cell
pellet was lysed in four pellet volumes of 6 M urea, 2 M thiourea in 100
mM Tris/HCl pH 8.5 (lysis buffer). The three lysates were sonicated on
ice (Branson sonifier, narrow tip, 40%) for a total sonication time of
140 s with 20 s on, 20 s off cycles. Protein yields were determined by
Bradford’s assay to be 40–45 mg per lysate. Samples were reduced
by addition of DTT to 1 mM for 30 min at room temperature, followed
by alkylation with 5 mM iodoacetamide during centrifugation at
20,000 g for 30 min at room temperature in the dark. Any remaining
debris was cleared from supernatants by 0.2 m filtration. Per con-
dition, 40 mg protein was carried forward. Each was digested by
incubation with 1:200 (w:w) ratio LysC/protein (200 g, Wako, Japan)
at room temperature for 4 h. Peptide samples were diluted four times
with 50 mM ammonium bicarbonate before digestion each with 1:400
(w:w) ratio trypsin/protein (100 g - SIGMA trypsin gold) for 16 h at
room temperature. Digestions were halted by acidification with addi-
tion of 10% trifluoroacetic acid (TFA) solution to pH 2–3 (to 0.6%
TFA v:v). Precipitate was removed by centrifugation at 3000  g for
15 mins before 0.2 m filtration. For each sample peptides were
purified by C18 reverse phase chromatography using spin columns
(two Waters Sep-Pak, 6cc, 1 g cartridges per condition) as described
by the manufacturers. Peptides were eluted from columns by 70%
ACN in 0.1% TFA. Peptide concentrations were estimated using OD
260 and OD 280 measurements and the Warburg-Christian method.
A volume equivalent to 300 g peptide was removed for each batch
(for use as “Crude” analysis) and these along with the remaining
peptide samples were lyophilized in a vacuum centrifuge attempting
to avoid over-drying. The 300 g Crude samples were each resus-
pended to a concentration of 0.85 mg.ml1 in 0.5% acetic acid, 0.1%
TFA and carried forward for MS analysis. The remaining peptides
were resuspended in 2 ml IP buffer (50 mM Tris/HCl pH 8.0, 100 mM
NaCl). Any undissolved peptides were removed by centrifugation at
20000g for 30 min. Peptide solutions were requantified by the War-
burg-Christian method to be 3.9–4.2 mg. ml1. To purify acetylated
lysine peptides, immune affinity chromatography was used. Briefly:
60l anti-acetylated lysine agarose beads (ImmuneChem) pre-equil-
ibrated with IP buffer was mixed with each peptide solution for 16 h
at 4 °C. The resin was washed three times with 1 ml IP buffer before
elution of peptides with three washes with 100 l 0.1% TFA. Peptide
solutions were desalted using two 4 ply STAGE tips per prep, and
lyophilized peptide elutions resuspended in 60 l 0.5% acetic acid,
0.1% TFA. These were carried forward for MS analysis as ‘IP’ sam-
ples for each treatment.
For the SILAC experiment investigating dynamics of aspirin-medi-
ated lysine acetylation a single 150 mm dish of cells was cultured for
each time point, except the 8h aspirin, 0h recovery condition, which
had 8 plates because it was being used as a reference (see Fig. 6 C
for experimental design). All treatments and purifications were carried
out essentially as described above but scaling down to account for
lower starting protein amounts. Five SILAC mixes labeled A to E were
prepared, each with initial total protein amounts of 2–5 mg, and with
the three SILAC conditions being mixed 1:1:1 (protein w:w:w) accord-
ing to Bradford’s assay.
MS Analysis of Peptide Samples—Peptide samples were analyzed
by LC-MS/MS on a Q Exactive mass spectrometer (Thermo Fisher
Scientific) coupled to an EASY-nLC 1000 liquid chromatography sys-
tem (Thermo Scientific) via an EASY-Spray ion source (Thermo Fisher
Scientific). Peptides were fractionated on a 75 m  500 mm EASY-
Spray column (Thermo Scientific) over various gradient lengths from
90 min to 240 min. The following describes the typical analytical
set-up, but further specific details of MS run conditions can be found
within the raw data files. Precursor ion full scan spectra were acquired
over (m/z 300 to 1,800) with a resolution of 70,000 at m/z 200 (target
value of 1,000,000 ions, maximum injection time 20 ms). Up to ten
data dependent MS2 spectra were acquired with a resolution of
17,500 at m/z 200 (target value of 500,000 ions, maximum injection
time 60 ms). Ions with unassigned charge state, and singly or highly
(8) charged ions were rejected. Intensity threshold was set to 2.1 
104 units. Peptide match was set to preferred, and dynamic exclusion
option was enabled (exclusion duration 40 s). The mass spectrometry
proteomics raw data files have been deposited to the Proteome-
Xchange Consortium via the PRIDE partner repository (http://
www.ebi.ac.uk/pride/archive/) with the dataset identifier PXD003530
for the label-free site ID analysis, and PXD004995 for the occupancy
and SILAC half-life analysis.
MS Data Analysis—Raw MS data files were processed using Max-
Quant software (version 1.3.0.5) (21, 22) and searched against Uni-
ProtKB human proteome (86749 sequences - 13/06/2012) and the
built-in “contaminants” list. The variable modification for lysine acety-
lated by aspirin was defined in Andromeda to allow automated data-
base searching for Acetyl-d3 K. Specificity was considered only for
lysines, composition was set to H-1C2OHx3 (monoisotopic mass
45.029394924), position at peptide C termini was excluded, and two
diagnostic peaks were defined; H8C7ONHx3 (128.1028942181) and
H11C7ON2Hx3 (145.1294433196). For RAW data analysis in Max-
Quant enzyme specificity was set to trypsin/P, cleaving C-terminal to
lysine or arginine. Lysine and arginine were selected as special amino
acid and a maximum number of three missed cleavages were al-
lowed. Carbamidomethylation of cysteines was set as a fixed modi-
fication and oxidation of methionines, acetylation of protein N termini,
acetylation of lysines and d3-acetylation of lysines were set as vari-
able modifications. A minimum peptide length was set to seven amino
acids and a maximum peptide mass was 5000 Da. A false discovery
rate of 1% was set as a threshold at protein, peptide and site levels,
and a mass deviation of 6 ppm was set for main search and 20 ppm
for MS2 peaks. MaxQuant output files have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository (see
above), and MS/MS spectra can be viewed on MS-Viewer (http://
msviewer.ucsf.edu/prospector/cgi-bin/msform.cgi?formmsviewer)
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using the search keys 4iznb5zvfu (label-free study) and kjfmg24iwf
(SILAC study).
The final list of aspirin-mediated lysine acetylation sites was cre-
ated by filtering the MaxQuant output removing sites by the following
criteria; (a) Peptides derived from the decoy database, (b) Sites with
localization probability lower than 0.75, (c) Peptides with mass error
greater than 2 ppm after mass recalibration. (d) Peptides of only
bovine origin. (e) Peptides that had the best evidence for modification
come from a sample not treated with aspirin-d3. Protein copy number
values were calculated using the label-free proteomic ruler method
(23) using a ploidy value of 3.4 based on the 76–80 chromosome
estimate for HeLa cells, compared with the usual 46 for human cells.
Sequence Logo Analysis—Sequence logos were generated by
plogo v1.2.0 (24). For aspirin sites 12069 31 residue sequence win-
dows were submitted, of which 11370 were processed. For the en-
dogenous sites 1473 were submitted, of which 1273 were processed.
“Endogenous” sites were defined as those sites where the file con-
taining the spectrum with the best localization probability was found
in nonaspirin-treated cells. Background was the human proteome,
n  660373.
Secondary structure and solvent exposure predictions—All pep-
tides were expanded to their whole protein “parent” and submitted to
Jpred v4 (25) for protein secondary structure prediction. Jpred has
length and time limits for making predictions where any protein longer
than 800 amino acids or shorter than 20 amino acids, or where a
prediction takes longer than 1 h will not get a prediction. Thus, a small
number of proteins do not get a secondary structure prediction.
DisEMBL disorder prediction (26) was performed via JabaWS (27).
The central lysine residue for each peptide was then interrogated in its
parent protein for its secondary structure and disorder prediction and
assigned as being either in helical, beta strand or coil, and disordered
or non-disordered region. Any peptides missing secondary structure
predictions were ignored. The counts for each of the five states were
summed across all peptides in a particular set and then compared
between sets. As predicted secondary structure from Jpred can only
be one of three states the comparison was at the level of proportion
of each state between sets. The Wald method was used to determine
the 95% confidence interval on the proportions of each state in each
data set:
S S
1.962
2
n n 1.962
p
S
n
CI0.95 1.96 p1 p	n
Where S is the number of lysines in a given state, and n is the total
number of lysines in a given dataset. Similar methods were applied to
solvent exposure calculations, which is also provided by Jpred. In this
case the majority of lysines are predicted to be solvent exposed so
comparisons were made on those with a predicted solvent exposure
of 25% or less.
SILAC Analysis of Aspirin-mediated Acetylation Decay—MS data
derived from the five SILAC mixtures described above were pro-
cessed by MaxQuant essentially as described above for the label-free
experiment. The match between runs, and requantify options were
selected in MaxQuant to allow identifications among “experiments” to
be used in all, and to provide ratios for modified peptides even in
absence of a heavy counterpart. The reported list of identified sites
was filtered to remove: (a) Peptides derived from the decoy database,
(b) sites with localization probability lower than 0.75, (c) peptides with
mass error greater than 2 ppm after mass recalibration, (d) peptides
with no reported SILAC ratios. This removed 2061 sites. SILAC ratios
were manually normalized using the median normalization factor cre-
ated by MaxQuant for the Crude data, for each reported ratio. These
normalized SILAC ratios for each “Mix” were used to calculate relative
acetylation at each time point. Acetylation was set to 100% for time
t  8 h exposure to aspirin-d3 (0 h recovery), and % acetylated for all
other time points was calculated by average of two methods using all
three SILAC ratios reported in a single mix. For example, for “Mix D”
(L  8 h Aspirin, M  8 h aspirin 
 0.25 h recovery, and H  8 h
aspirin 
 0.5 h recovery);
% acetylated at 8.25 h according to M/L ratio;
A8.251 100M/L	mixD (Eq. 1)
or % acetylated at 8.25 h according to H/L and H/M ratios;
A8.252 100H/L	mixD/H/M	mixD (Eq. 2)
 % acetylated at 8.25 h,
A8.25 A8.251 A8.252	/2 (Eq. 3)
% acetylated at 8.5 h according to H/L ratio;
A8.51 100H/L	mixD (Eq. 4)
or % acetylated at 8.5 h according to M/L and H/M ratios;
A8.52 100M/L	mixD  H/M	mixD (Eq. 5)
 % acetylated at 8.5 h;
A8.5 A8.51 A8.52	/2 (Eq. 6)
Data points corresponding to mixes without SILAC ratios were not
included in the analysis. Data were fit to a single phase exponential
decay by non-linear regression using GraphPad Prism version 6.0f
(GraphPad Software, Inc.). Plateau was constrained to 0% acetylation
and only positive K values were considered. Any sites reported by
Prism as “Too few points,” “Hit constraint,” or “Not converged” were
rejected. For the remainder, only sites with R squared value of 0.85
and a minimum of 9 data points were shortlisted. Any of these with
acetylation profiles characteristic of exogenous proteins (extremely
short half-lives and potentially of bovine origin), were rejected. Of a
total of 6942 sites remaining after initial filtering, this secondary filter-
ing left a list of 1480 sites of aspirin-mediated acetylation of human
proteins with good quality decay data.
Acetylation site Occupancy Calculation—A SILAC experiment was
conducted with HeLa cells grown in the heavy (H) condition treated
with DMSO, and the light (L) condition treated with 5 mM aspirin-d3 for
8 h (Fig. 5B). A third SILAC condition (medium or M) was included,
which was treated with 5 mM aspirin-d3 for 15 min. This was included
in case of issues associated with requantification of acetylated pep-
tides in H/L comparisons, but eventually acetylated peptide ratios
were not required for occupancy calculation, so the M condition was
unnecessary. This SILAC mixture is referred to as “occupancy mix-
ture” or “Mix O.” The cells from Mix O and the resultant MS data were
processed in parallel with those used for acetylation half-life analysis
(described above). Acetylation site identifications from all mixtures
(Mixes A to E and Mix O) were used to define a set of unmodified
counterpart peptides as described in Fig. 5A. All unmodified coun-
terpart peptides identified and quantified from Mix O were used to
calculate acetylation site occupancy using equation 7. See Fig. 5C
and 5D for derivation.
Occupancy % 1 Pr/Ur	 100 (Eq. 7)
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Where Pr and Ur are the H/L ratios for the total protein and unmod-
ified counterpart peptide of each acetylated peptide. For reference,
occupancy calculations were also applied to a control set of peptides
not designated as unmodified counterparts. These were used as a
presumptive negative control set with which the known unmodified
counterparts could be compared.
Other Statistical Analyses—Survival assays were made with n  4
replicates and differences between conditions measured by St-
udent’s nonpaired two tailed t test assuming equal variance. For
acetylated lysine half-life analysis, the 1480 sites were divided into 6
subsections based on half-life using 6 h bins: 1, 0–6 h; 2, 6–12 h; 3,
12–18 h; 4, 18–24 h; 5, 24–30 h; and 6, 30 h. Annotation of known
acetylation, ubiquitination and SUMOylation sites, GO terms, Pfam
families and KEGG pathways were annotated to each site in Perseus
using the most up-to-date annotations files and comparison with
published data (28, 29). Relative enrichment of these in each sub-
section was calculated by Fishers exact test in Perseus. Only values
with a Benjamini-Hochberg FDR of 1% in at least one sub-section
were used in the heatmap. Hierarchical clustering was performed
using the Euclidian method calculating distances by averages using
Perseus-reported enrichment factor scores for each category in each
subsection.
Comparisons among subsections for significant differences be-
tween numerical means of protein half-life (from reference (30)) used
the Student’s t test (comparing each sub-section with an equally
sized random sample of the entire set). The two-tailed test was
employed using either a two-sample equal variance method, or two
sample unequal variance method depending on whether the variance
ratio was less or greater than 1.5 respectively.
For occupancy calculations, comparisons between the values cal-
culated for true unmodified counterpart peptides, and those not
thought to be unmodified counterparts, the two-tailed unpaired St-
udent’s t test was applied using Welch’s correction.
RESULTS
Aspirin Cytotoxicity in HeLa Cells is Largely Independent of
Protein Acetylation—The toxicity of aspirin to HeLa cells (hu-
man cervical cancer) was assessed by survival assay over a
range of drug concentrations and exposure durations (Fig.
1A–1C). To try to specifically isolate the influence of acetyla-
tion on toxicity, comparisons were made with the non-acety-
lating metabolite of aspirin, salicylic acid (SA). After 6 h,
greater than 90% cell survival was observed for aspirin con-
centrations of 5 mM or less (Fig. 1A). SA showed similar, if
slightly higher toxicity over the same duration (Fig. 1A). Longer
exposures to aspirin and SA caused increased cell death (Fig.
1B, 1C), although large differences between the two were not
observed.
To establish the kinetics of aspirin uptake and hydrolysis
under cultured cell conditions, aspirin and salicylic acid
levels were monitored during 24 h exposure to 5 mM aspirin.
The measurements fit well to a model whereby aspirin dif-
fuses across the cell membrane more rapidly than salicylic
acid (SA), and is hydrolyzed to SA around 200 times faster
in the cell than the medium (supplemental Fig. S1A–S1C).
As a result intracellular aspirin is consistently 40% of the
medium concentration (supplemental Fig. S1A, S1E). Thus
intracellular aspirin concentrations are closely linked to the
extracellular concentration, and administration or removal
of aspirin is relatively quickly mirrored by intracellular
changes.
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FIG. 1. Aspirin-d3 acetylates proteins in cultured cells. A–C, Survival assays comparing aspirin and salicylic acid for death of HeLa cells
over a range of concentrations from 0.5 to 20 mM, and over a range of durations; 6 h (A), 24 h (B), and 48 h (C). Four replicates were averaged
and standard deviations are indicated as error bars. t test p values are indicated by asterisks (see below panel B). D, Schematic overview of
the acetylation of the -amino-group on lysine side-chains by aspirin-d3. The acetyl-d3 group is distinguishable from the non-deuterated
equivalent by 3 Da. E, Anti-acetylated lysine immunoblot analysis of crude cell lysates from HeLa cells exposed to the indicated
concentrations of commercially sourced aspirin, in house synthesized unlabeled aspirin or in-house synthesized aspirin-d3 for 4 h. Single and
double asterisks indicate positions of the most abundantly acetylated proteins in untreated cells (discussed further in relation to Fig. 3A).
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Unambiguous Definition of the Aspirin-mediated Lysine
Acetylome in HeLa Cells—The addition of a single acetyl group
(CH3CO) to a protein causes an increase in mass of 42.01 Da.
To allow discrimination between endogenous acetylation and
aspirin-mediated acetylation, labeled aspirin-d3 was synthe-
sized in which the three hydrogen atoms of the acetyl group are
substituted with deuterium (supplemental Fig. S2A–S2C). This
does not affect aspirin reactivity, but resultant acetylations will
be3 Da heavier than endogenous equivalents (Fig. 1D), which
is easily discriminated by modern mass-spectrometry instru-
mentation (supplemental Fig. S3).
Commercially obtained aspirin, in-house synthesized aspi-
rin, and in-house synthesized aspirin-d3 displayed indistin-
guishable patterns of acetylated species in anti-AcK West-
ern blots of cell lysates (Fig. 1E). It appears that dose has
little influence on protein selection, as higher concentrations
only increase the intensity of acetylated species, rather than
change the pattern of conjugates (Fig. 1E).
To identify sites of acetylation a large-scale mass-spec-
trometry-based proteomics experiment was undertaken (Fig.
2A). Our study concentrated on acetylation of lysines because
this PTM has well-established biological functions, and be-
cause the enrichment of nonlysine acetylated peptides is
prohibited by the absence of suitable reagents. Three groups
of cultured HeLa cells were exposed to 5 mM aspirin (unla-
beled/isotopically typical form), 5 mM aspirin-d3, or vehicle
control for four hours. This dose was chosen as it was non-
toxic, gave a high level of acetylation (Figs. 1E, supplemental
Fig. S4) and is representative of the concentrations used in
previous cellular protein acetylation studies (12–14, 16, 19,
31–33). For each experimental condition a Lys-C/trypsin di-
gest of unfractionated cell extract, designated ‘crude’ and an
anti-AcK peptide preparation, made by immuno-precipitation
(IP) of peptides using an anti-AcK antibody (17, 34, 35) were
prepared. This allows both total proteome and acetylated
peptide analysis (Fig. 2A) by LC-MS/MS (21, 22) searching for
lysine modifications by acetylation (MW 42.01) and d3-
acetylation (MW 45.03). Example spectra for both unlabeled
and d3-labeled-acetylation of transaldolase at Lys
81 are
shown in supplemental Fig. S5.
After extensive filtering of the data (see Experimental Pro-
cedures for criteria), a total of 12069 aspirin-d3-mediated
lysine d3-acetylation sites were identified in 3763 proteins
(supplemental File. S1). Similar numbers of isotopically typical
acetylation sites were found from cells treated with unlabeled
aspirin (Fig. 2B). Only 94 d3-AcK sites were found in the
unlabeled aspirin preps (Fig. 2B), where no d3-AcK sites
should be expected, suggesting an actual false-positive rate
in the order of 0.8%. There was a 73% overlap between
labeled and unlabeled aspirin acetylation sites (Fig. 2C), con-
sistent with the expected overlap between biological repli-
cates of shotgun proteomics studies of this scale.
Untreated cells only yielded 1472 acetylation sites (Fig. 2B,
2C) with 70% overlap between this and the aspirin acetylome
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(Fig. 2C, 1039/1472 endogenous sites). Thus, aspirin targets a
large proportion of lysine residues that are also endogenously
modified. Unexpectedly, only 162 isotopically typical (endog-
enous) AcK sites were identified in preparations from aspi-
rin-d3 treated cells (Fig. 2B), one-tenth of those found in
DMSO treated cells. It is unlikely that aspirin administration
suppressed endogenous acetylation, rather the MS analysis
favored detection of the more abundant and numerous d3-
acetylated peptides.
Semiquantitative comparisons between preps showed that
both aspirin types gave broadly equivalent ion intensity data,
confirming the labeled aspirin behaved identically to its unla-
beled counterpart (Fig. 2D–2F).
Except for Histone N-terminal Tails, SMC3 and Enzymes
Involved in Acetylation Aspirin Considerably Increases Exist-
ing Endogenous Acetylations—MS signal intensity correlates
only weakly with absolute peptide abundance when compar-
ing different peptides, but across a large mixed population,
frequency distributions of peptide intensities are indicative of
the dynamic range of abundance. Analysis of these data
suggests that endogenously acetylated peptides are generally
less abundant than aspirin-mediated acetylated peptides, but
there is a small number of extremely abundant endogenous
acetylations with peptide intensities three to four orders of
magnitude higher than the median, that are not found acety-
lated to the same degree by aspirin (supplemental Fig. S6A–
S6C). This is consistent with anti-AcK Western blots that
show only a few apparently acetylated species in untreated
cells, but a broad range in aspirin treated cells (Fig. 1E).
Direct comparisons between DMSO and aspirin-d3 treated
preps for common (n  1039) acetylated peptide signal in-
tensity, allow evaluation of the relative abundance of each in
the different conditions (Fig. 3A, 3B). This specifically ad-
dresses the question; to what extent does aspirin modify
lysine residues that are also acceptors for endogenous acety-
lation? Peptides for which d3-AcK intensity is approximately
the same as endogenous AcK intensity, will be found close to
the 1:1 (equivalence) line in scatter plots (Fig. 3A) and with
log2 ratios close to 0 (Fig. 3B). Those for which aspirin adds
more than was already present will be found above the 1:1 line
(Fig. 3A) or with positive log2 ratio values (Fig. 3B magenta),
and those for which aspirin adds less than was already pres-
ent, below the line (Fig. 3A) and with negative log2 ratio values
(Fig, 3B yellow). These show that the vast majority of endog-
enously acetylated peptides were considerably more acety-
lated during aspirin treatment (on average 15 fold increased).
Over 82% of endogenous acetylations, had d3-acetylated
equivalents that were more than twice as abundant, 63%
were 10-fold more abundant, and 22% of endogenous sites
were more than 100-fold more acetylated in the presence of
aspirin (Fig. 3A). As overall protein levels do not significantly
change among preps (Fig. 2D), these results are explained by
aspirin causing increased stoichiometry of acetylation at sites
already acetylated in untreated cells.
In contrast to the general multifold amplification of endog-
enous acetylation by aspirin, some proteins have their acety-
lation signals less than doubled. In other words, aspirin adds
fewer acetyl groups than was already present (Fig. 3A yellow).
Among the rare group of proteins with 1:1 aspirin/endoge-
nous acetylation are those which are themselves involved in
acetyl group metabolism, such as acetylCoA synthetase, fatty
acid synthetase, and N-acetyl transferase (Fig. 3B, blue). But
the most striking set of proteins are those for which aspirin
adds less than 10% of existing acetylation (Fig. 3A below 10:1
line), which contain a preponderance of histone sites (Fig. 3A,
3B red). In fact, of this group only one belongs to a non-
histone protein (Fig. 3A asterisk), Lys106 from SMC3, which is
known to be required for sister chromatid cohesion during
S-phase of the cell cycle (36).
These observations are consistent with the idea that aspirin
does not add a great deal more to the existing pool of acety-
lated protein if that protein is already highly acetylated under
normal conditions. Indeed, by calculating the proportion of
the total acetylated peptide signal intensity that is derived
from histones (Fig. 3C), it is clear that histone acetylation
makes up almost 90% of endogenous signal. In contrast,
histone acetylations represent about 10% of the acetylated
peptide signal intensity in aspirin treated cells. This suggests
the two most abundant anti-AcK-reactive species found in
extracts from untreated cells (Fig. 1E asterisks) are SMC3
(142kDa) and histones (11–22kDa) acetylations.
Although most histone acetylations are largely unaffected
by aspirin, a few appear to have their acetylation site occu-
pancy increased 10-fold or more by aspirin (Fig. 3A, 3B).
Some are over 100 times more acetylated by aspirin, and 20
d3-acetylation sites that were detected in aspirin-d3 preps
were not detected in preps from DMSO treated cells, sug-
gesting trace or absent acetylation under normal conditions.
Strikingly, it is the N-terminal tail regions that are least af-
fected by aspirin, while all others are amplified considerably
by aspirin (Fig. 3D, 3E). These sites are predominantly either
buried in the nucleosome core structure or in regions contact-
ing DNA.
Detection of an Aspirin-mediated Lysine Acetylation De-
pends Largely on the Cellular Abundance of the Protein—The
12,069 aspirin-AcK sites identified in this study were identified
from 3763 proteins, and 1472 endogenous AcK sites were
identified in 746 proteins. Comparing site frequency per pro-
tein (supplemental Fig. S7A, S7B) shows that less than half of
the aspirin targeted proteins had only a single detectable site,
whereas two-thirds of the endogenous group had only a
single site identified. Also, almost 5% of proteins were found
to have more than ten aspirin acetylation sites, whereas only
0.6% of proteins from untreated preps were similarly modi-
fied. This group of aspirin hyper-acetylated proteins are com-
monly involved in cell structure; Plectin (105 sites), myosin-9
(64 sites), Filamin-A and B (56 and 44 sites), AHNAK/des-
moyokin (52 sites), and dynein 1 heavy chain 1 (45 sites),
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which are among the most abundant proteins in the cell.
Indeed, estimates of copy-number per cell (23), correlate with
acetylated peptide intensity better for the aspirin data than the
endogenous data (supplemental Fig. S7C, S7D), indicating
that the more abundant a protein is in the cell, the more likely
that its acetylated peptides are detected in shotgun proteom-
ics studies such as this. Consistent with this, proteins detect-
ably acetylated by aspirin do not show any significant enrich-
ment for functional group over a control list of proteins derived
from shotgun MS analysis of the crude HeLa cell lysate (Fig.
4A, left). This is in contrast with a SUMOylation site list pre-
pared from the same cell type, which shows some consider-
able differences between crude and purified data sets (Fig.
4A, right).
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Many PTMs have been studied on the proteomic scale
giving over 30,000 acetylation, 60,000 ubiquitination and 5000
SUMOylation sites (PhosphoSitePlus®, www.phosphosite.
org, (28, 29, 37)). Comparisons with these (Fig. 4B, supple-
mental Fig. S8), show that the aspirin acetylation sites overlap
more with ubiquitination sites than known acetylation sites.
This contrasts with the “endogenous” acetylation sites de-
tected in this study, which as expected shows greater over-
lap with known acetylation sites than ubiquitination sites.
The precise statistical significances of these intersections
cannot be calculated without knowledge of the total detect-
able proteome, but the data so far imply that aspirin appears
to have not only the potential to amplify endogenous acety-
lation signals, but also to interfere with protein stability.
Secondary structure and solvent exposure comparisons
(38) show a significant overrepresentation of helical regions
(Fig. 4C left), and an underrepresentation of buried lysines
(Fig. 4C right) in the aspirin acetylome compared with a back-
ground lysine set. Solvent exposure will be critical for acety-
lation by a chemical, but the reason for the apparent bias
toward helical domains is presently unclear. Sequence anal-
ysis (24) shows aspirin acetylations are commonly found
within acidic domains, with aspartic acid and glutamic acid
residues at positions 3 and 1 being most significantly
overrepresented (Fig. 4D–4G). Aspirin acetylation sites lack-
ing acidic residues within three amino-acids of the target
lysine (2645 sites uploaded) generate a logo with an over-
representation of leucine, phenylalanine and tyrosine in the

1 position, as is common to endogenous sites (1273 sites
uploaded) (Fig. 4E, 4F). It may be that a sub-population of
aspirin-mediated acetylations share a functional link with en-
dogenous acetylations, perhaps by recycling of aspirin acetyl
groups into endogenous acetylation systems. Further se-
quence analysis shows some interdependence between ami-
no-acids proximal to acetylated lysines, most strikingly the
relationship between leucine and phenylalanine in the 
1
position and acidic residues in the 1 and 3 positions
(supplemental Fig. S9). Acetyl phosphate (AcP) chemically
acetylates lysines in bacteria (39), and sequence analysis of
published sites also shows a similar propensity for acidic
regions (supplemental Fig. S10). Together these data confirm
aspirin acetylates in a non-enzymatic fashion expressing no
particular preference for targets based on cellular location or
function.
Aspirin Acetylation Site Occupancies Are Low—Although
we can identify sites of acetylation, and compare relative
abundance between aspirin acetylations and endogenous
equivalents, it is important to know the proportion of a protein
that is acetylated by aspirin. This is critical for the evaluation
of the potential to alter protein function either by introduction
of a new chemical signal or by competition with other PTMs.
Attempts to determine site occupancy or stoichiometry for
phosphorylations have shown them to be very high, with
median values of between 50 and 90% for a variety of kinase
substrates (40), while protein acetylation in yeast and human
cells is reported to be low, in the 0–10% range (41, 42).
Proteomic-based occupancy calculations rely heavily on
changes in unmodified counterpart peptide (Fig. 5A) abun-
dance during a stimulation or treatment that alters modifica-
tion status. As such, calculations of site occupancy are more
accurate when the difference in modification between the two
experimental conditions is large. As there is no aspirin-medi-
ated acetylation in absence of aspirin, a SILAC experiment
was designed to compare untreated cells with those treated
with aspirin (Fig. 5B) that allows occupancy calculation using
only unmodified peptide and total protein ratios (Fig. 5C, 5D).
However, even with high quality SILAC data, changes in un-
modified counterpart peptides were so small (Fig. 5E) that
calculations often failed to provide a positive value for occu-
pancy (supplemental File S2). Frequency distributions of as-
pirin acetylation occupancy values were normally distributed
around 0.15% (Fig. 5F). Indeed, the calculated aspirin-medi-
ated acetylation occupancies were not significantly different
from those of a control set of peptides not identified as
unmodified counterpart peptides (Fig. 5F, 5G). This implies
that aspirin acetylation affects only a very small proportion of
the total pool of any protein, with median occupancy being
less than 1%.
Aspirin-mediated Lysine Acetylations Have a Wide Range of
Half-lives in Cultured Cells—Although aspirin-mediated acety-
lations are know to persist for hours after removal of the drug
(18), the dynamics on the individual site level have not been
explored. Anti-AcK western-blot analysis suggests that even
24 h after exposure, some aspirin acetylations are still present
(Fig. 6A, 6B). A time-resolved SILAC experiment was under-
taken to quantitatively monitor AcK peptide abundance after
drug withdrawal, and derive an acetylation half-life for each
site. In the experiment a “Light” labeled SILAC reference
sample was prepared from cells treated with 5 mM aspirin-d3
for 8 h. Ten further cultures of “Medium” and “Heavy” labeled
cells were also incubated with 5 mM aspirin-d3 for 8 h before
the culture medium was replaced with medium lacking aspi-
rin, for varying lengths of time prior to harvesting (Fig. 6C).
Thus, it was theoretically possible to obtain quantitative infor-
mation on acetylation sites with 10 data points over a 48 h
time-course. In practice, only 1480 sites provided good
enough data to fit to an exponential decay model and yield
reliable half-life values (supplemental File S3). These data
encompassed a large range of half-lives from 1 h 23 min for
acetylation at Lys49 of mitochondrial ATPase inhibitor ATPIF1,
to 40 h 24 m for acetylation at Lys215 of mitochondrial malate
dehydrogenase MDH2. The median half-life was 21 h.
Growth retardation is likely to explain why around a third of
half-lives were calculated as greater than the typical doubling
time of HeLa cells of 24 h.
Examples of raw data for three multiply modified proteins
and overall data for thirteen proteins are shown in Fig. 6D.
Nucleophosmin, which is thought to have roles in nucleosome
Aspirin-mediated Lysine Acetylation
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Aspirin-mediated Lysine Acetylation
Molecular & Cellular Proteomics 16.2 321
structure, ribosome biogenesis, genomic stability, apoptosis,
p53 signaling, and centrosome duplication, contains two of
the three shortest half-life sites at Lys141 and Lys266 (2 h 4 m
and 2 h 15 m). It also has two sites with longer half-lives at
Lys257 and Lys32 (7 h 46 m and 25 h 32 m). In contrast, other
multiply-acetylated proteins such as HSPA8, HSPA9, Annexin
A2, and Asparate aminotransferase displayed acetylation
half-lives within a 7h range (Fig. 6D). To determine whether
there is any broader relationship between aspirin-mediated
lysine acetylation half-life and protein function a GO, KEGG
and PFam enrichment analysis was undertaken. Despite the
large number of categories considered, only a small number
showed significant enrichment in any single subsection.
These included acetylation of MHC complex components
	-2-microglobulin (Lys61 and Lys68) and HLA class I histo-
compatibility antigen (Lys145 and Lys151) with half-lives of less
than 12 h. Mitochondrial proteins tended to be over-repre-
sented in long half-life groups, as were, to a lesser degree
vesicular proteins (Fig. 6E upper heatmap). Proteins from
the nucleus and nucleolus and those associated with chro-
matin tended to have low acetylation persistence (Fig. 6E
upper heatmap), implying relatively rapid reversal in these
compartments.
Two active biological processes will impact on the rate of
decay of an acetylation signal in cultured cells; the rate of
protein turnover, and the action of cellular lysine deacetylases
(KDACs). Two proteomic studies measuring protein turnover
rate (30) and assessing the influence of KDAC inhibitors on
endogenous acetylation (43) were compared with the acety-
lation half-life data (Fig. 6E lower heatmap and Fig. 6F). This
showed that short half-life sites were commonly sensitive to
the HDAC6 inhibitor bufexamac (44), and the sirtuin inhibitor
nicotinamide (45). Protein turnover rate has a significant, but
weaker influence upon acetylation half-life (Fig 6F), although
for the majority protein turnover half-life is much longer than
acetylation half-life (supplemental Fig. S11). SUMO sites that
are also acetylated by aspirin tend to lose acetylation quickly
(Fig. 6E small upper heatmap), which is possibly a conse-
quence of the fact SUMO substrates are typically nuclear, a
cellular location rich in proteins with short acetylation half-
lives (Fig. 6E). Conversely, known acetylation sites are more
common in the long half-life sub-group, probably because
endogenous acetylations will have the same half-lives as as-
pirin-mediated ones, and slow removal makes identification in
proteomics experiments more likely.
Bufexamac Enhances Aspirin-mediated Cytotoxicity—To
explore the influence of bufexamac and nicotinamide on as-
pirin-mediated protein acetylation, protein acetylation and cy-
totoxicity in HeLa cells was investigated. Both bufexamac and
nicotinamide delay deacetylation in cells exposed to 5 mM
aspirin for 5 h (Fig. 7A). Bufexamac (0.25 mM) significantly
increases aspirin-mediated cytotoxicity, lowering the concen-
tration of aspirin required to kill 50% of cultured cells from
7.3 mM to 0.9 mM (Fig. 7B middle chart). Under the same
conditions, it only modestly reduces salicylic acid cytotox-
icity from 8.3 mM to 3.1 mM. Nicotinamide has a small and
equal effect on the toxicity of both aspirin and salicylic acid
(Fig. 7B, lower chart). This result is consistent with KDAC
inhibition sensitizing cells to the toxic affects of aspirin-
mediated protein acetylation. These results are consistent
with previous work showing synergy between aspirin and
the KDAC inhibitors suberoylanilide hydroxamic acid and
sodium butyrate in induction of ovarian cancer cell death
(46).
DISCUSSION
The discovery that aspirin functions as an NSAID by acety-
lation of COX enzymes (7, 8), created a paradigm for the
action of aspirin: Acetylation of a specific protein leads to a
biologically relevant outcome. This model has been expanded
to explain other functions of the drug via acetylation of intra-
and extra-cellular proteins (8–10, 12–14, 16, 19, 31–33, 47).
Proteomics approaches using cultured cells and modified
forms of the drug have shown that aspirin’s ability to acetylate
extends beyond a handful of proteins (14, 18, 19), but critical
details such as the relative scale of aspirin-mediated acetyla-
tion and site stoichiometry were not explored.
We have used isotopically labeled aspirin-d3, in combina-
tion with peptide level anti-AcK antibody affinity purification
and current LC-MS/MS instrumentation to identify over 12000
sites of aspirin-mediated lysine acetylation from cultured hu-
man cells. The majority of endogenous lysine acetylations are
greatly amplified by aspirin, often by orders of magnitude, but
despite this, site stoichiometry is low by comparison with
other signaling PTMs such as phosphorylation (40). Even after
extended exposures to millimolar quantities of aspirin, as is
Half-lives of selected proteins with multiple site data. E, Analysis of 1480 aspirin acetylation sites data by separation into six sub-sections (1,
0–6 h, n 47; 2, 6–12 h, n 135; 3,12–18 h, n 287; 4, 18–24 h, n 541; 5, 24–30 h, n 421; and 6,30 h, n 49) on the basis of half-life
as shown in the central scatter plot and lateral histogram. Large upper heatmap shows hierarchial clustering of GO, Pfam and KEGG terms
enriched in the six sub-sections. Only groups with a Benjamini-Hochberg FDR 1% in at least one subsection were included in the figure.
Multiple sites from the same protein were considered as separate entries. Enrichments calculated in Perseus using Fishers exact test. Small,
upper heatmap shows the same analysis for enrichment of sites already described as being modified by SUMO-2, ubiquitin or acetylation.
Lower heatmap shows hierarchical clustering of sub-section average log2 lysine deacetylase inhibitor KDACI/control ratios for lysine sites
identified in common between this study and those endogenous acetylations described in ref (43). F, Scatter plots show average protein
half-life per subsection as described in reference (30). p values according to t test comparisons with equally sized control groups of randomly
selected data are indicated.
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routinely used in functional studies, standard SILAC pro-
teomic methods are unable to accurately calculate stoichiom-
etry because of immeasurably small changes in unmodified
counterpart peptide abundances. In fact our data imply that
lysine acetylation stoichiometry, even during exposure to high
doses of aspirin, are for the majority, less than 1%. This
apparent paradox between large signal amplification and low
occupancy is explained by the fact that endogenous acetyla-
tions are for most, already at very low stoichiometry, being
typically much lower than 1% (41, 42). Thus, aspirin is simply
amplifying what is already a very low signal.
Conversely, aspirin did not greatly amplify the acetylation of
proteins that are already known to be important targets for
endogenous acetylation. Specifically, the modification of en-
zymes involved in the cellular acetylation system, the N-ter-
minal tails of histones and SMC3 were all only modestly
affected by aspirin. It has been noted that endogenous acety-
lation stoichiometry correlates closely with apparent biologi-
cal significance (41). It is therefore the case that those pro-
teins with relatively high endogenous acetylation are not
substantially altered after exposure of cells to aspirin. Indeed,
proteomic studies in yeast and bacteria reveal that low stoi-
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chiometry endogenous acetylations are likely to be nonenzy-
matic “lesions” caused by interactions between proteins and
reactive metabolites such as acetyl-CoA (41) and AcP (39)
(and reviewed in (48)). These observations are entirely con-
sistent with this study using aspirin, which is also acting as an
apparently unspecific acetylating chemical. It is thus likely that
a major role of lysine deacetylases is to remove this “chemical
noise” from the proteome. This supports the model of a
two-tiered cellular acetylation landscape, with one group of
relatively high stoichiometry and biological relevance, and
the other of low stoichiometry and relevance. The former are
more likely to be specifically generated by acetylating en-
zymes, while the latter may be predominantly of chemical
origin.
These findings suggest that without knowledge of acetyla-
tion site stoichiometry, the biological importance of previously
identified aspirin-mediated protein acetylations (12–14, 19,
31–33) is difficult to assess. Certainly, low stoichiometry al-
most completely excludes the possibility that aspirin can
compete with other lysine-specific PTMs such as ubiquitin.
However, it cannot be excluded that low stoichiometry may
still lead to an important biological outcome, it is likely this
would only exist in exceptional circumstances as cells tolerate
aspirin-induced, large-scale low occupancy acetylations very
well. It is also possible that in rare cases, aspirin could give
rise to high occupancy or high persistence acetylation. Taking
the COX enzymes as examples, it appears that an inherent
affinity for the aspirin molecule itself contributes toward the
direction of the chemical toward the active site (49). Further-
more, aspirin-mediated serine acetylation, as in the case for
COX enzymes, may be resistant to deacetylation because
endogenous enzymes are incapable of reversing the modifi-
cation. Notably aspirin-mediated serine acetylations seem to
be rare (19), suggesting they are not as reactive as lysines to
acetylating chemicals. Aspirin acetylations are commonly
found within regions containing acidic amino acids. A lysine
within a localized negative charge environment may have a
lower -amino-group pKa, tending more toward the deproto-
nated form under physiological conditions. Deprotonation is
required for nucleophilic attack by acetylating chemicals (50).
For this study we used relatively high doses of aspirin (4–5
mM), although such exposures are not uncommon for acety-
lation studies on cultured cells (12–14, 16, 19, 31–33). We
expect that different doses are more likely to affect site oc-
cupancy than alter site selectivity. Indeed, anti-AcK Western-
blots show different doses alter signal intensity rather than
species modified. Due to its hydrolysis in biological solutions,
different tissues will be exposed to different concentrations of
aspirin after administration. Although circulating plasma lev-
els of aspirin have been measured to be to be around
50–300 M after a typical analgesic dose of 300–600 mg
(51, 52), gut epithelia may be exposed to millimolar concen-
trations, while low perfusion tissues will encounter less. It is
therefore reasonable to assume that in the context of a
whole organism, cellular protein acetylation by aspirin will
depend largely on the balance between the local concen-
tration of the drug, and the activity of cellular deacetylases.
Whole organism acetylation studies will be revealing in this
context.
In conclusion, this work shows that although aspirin-me-
diated acetylation of proteins on lysine side-chains is
spread widely across the expressed proteome, it is mostly
at a low level. Scavenging lysine deacetylases work to limit
aspirin’s potential to interfere with canonical acetylation
signaling pathways, and blunt its ability to influence biolog-
ical processes.
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